Fractyl Health (NASDAQ:GUTS) (NASDAQ: GUTS) is a metabolic health company dedicated to developing minimally invasive, endoscopy-based interventions for chronic metabolic diseases, including type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Founded in 2014 and headquartered in Lexington, Massachusetts, the company seeks to address underlying intestinal pathologies that contribute to metabolic dysfunction by harnessing the therapeutic potential of targeted duodenal mucosal resurfacing.
At the core of Fractyl’s technological platform is Revita® DMR (Duodenal Mucosal Resurfacing), a catheter-based procedure performed through standard endoscopy. By gently ablating and regenerating the duodenal lining, Revita DMR aims to reset metabolic signaling pathways, improve glycemic control, and reduce hepatic fat accumulation. The company’s R&D pipeline also includes combination approaches pairing mucosal resurfacing with adjunctive pharmacotherapies and microbiome-modulating agents to extend clinical benefit across a broader patient population.
Fractyl’s Revita DMR received CE Mark approval in Europe and is being evaluated under multiple clinical trials in the United States and select international markets. The company collaborates with leading academic institutions, gastroenterology centers, and endocrinology networks to advance its clinical development program. These strategic partnerships are designed to optimize procedural protocols, patient selection criteria and long-term outcome tracking across diverse demographic and geographic cohorts.
Leadership at Fractyl Health includes CEO Dr. Aviv Bahat, who brings over two decades of experience in medical device innovation, and Chief Medical Officer Dr. Steven Stern, a gastroenterologist renowned for his expertise in endoscopic therapies. The company’s board features industry veterans from both the biopharmaceutical and medical device sectors. Together, this team is committed to transforming the treatment landscape for metabolic disease by offering durable, organ-targeted interventions that complement existing therapeutic options.
